Hope for Myasthenia Gravis Patients: Promising Results from Clinical Trial Did you know a recent trial for myasthenia gravis (MG) treatment showed a 4.70-point improvement? This is a big deal for the thousands of Americans with this disease1. Johnson & Johnson has made a big move by asking the FDA to approve nipocalimab. This is […]
